Smart Library
Faceted search across all 5 registries. Filter by registry type, evidence level, or safety domain.
New to hirudotherapy? Start here
This library indexes the full evidence base. For orientation, begin with the core guides:
Filters
Evidence level
Showing 293 of 730 entries. Refine via URL query params.
Conditions
174Venous Congestion in Surgical Flaps
Tier AFDA-cleared application: medicinal leech therapy to relieve venous congestion in compromised tissue flaps awaiting vascular ingrowth.
Microsurgical Replantation (Digit / Ear / Scalp)
Tier AFDA-cleared application: post-replantation venous decompression in digits, ears, scalp, and partial avulsion injuries.
Breast Reconstruction Flap Salvage
Tier AFDA-cleared application: venous decompression of compromised DIEP, TRAM, and latissimus dorsi flaps in post-mastectomy reconstruction.
Knee Osteoarthritis
Tier BOff-label use; several small RCTs in knee OA report pain and function improvement with leeches versus NSAID gel, sham leech or TENS, though results against sham and TENS are mixed, and a 2022 trial against physiotherapy found no therapeutic effect.
Rheumatoid Arthritis
Tier CNo published clinical study of leech therapy in rheumatoid arthritis was identified; early disease-modifying treatment remains the standard, and leeches must never replace or delay it.
Thumb Carpometacarpal (CMC-1) Osteoarthritis
Tier BOff-label use with one small RCT (Michalsen 2008, 32 women) in which single-session leech therapy reduced pain and improved hand function more than topical diclofenac for about 2 months.
Lateral Epicondylitis (Tennis Elbow)
Tier BOff-label use with one small RCT (Bäcker 2011, n=40) in which a single leech session reduced pain more than topical diclofenac at day 7; the pain difference was no longer significant at day 45.
Plantar Fasciitis
Tier CInvestigational use; no clinical study of leech therapy for plantar fasciitis was identified, and the rationale is mechanistic only.
Chronic Venous Insufficiency (CEAP C3-C5)
Tier BOff-label adjunct to compression; the journal evidence is one small open-label randomized trial in varicose veins (n=50) and a 20-patient uncontrolled series; the books describe further reports (see “What the books describe” below).
Venous Leg Ulcer
Tier BOff-label adjunct to compression therapy; the journal evidence is one 20-patient uncontrolled series in complicated varicose veins plus case reports; the books add an older report on trophic ulcers of unspecified origin (see “What the books describe” below).
Post-Thrombotic Syndrome
Tier CInvestigational use; no controlled trial was identified, and the only clinical report is a 1998 conference series of 87 patients without a comparison group.
Chronic Rhinosinusitis
Tier BInvestigational use for chronic rhinosinusitis; no clinical study of leech therapy for this condition was identified, and the rationale is mechanistic.
Cervical Radiculopathy
Tier CInvestigational use for cervical radiculopathy; no verifiable published trial specific to this indication.
Lumbar Radiculopathy (Sciatica)
Tier CInvestigational use for lumbar radiculopathy; the closest randomized evidence is in chronic low back pain (Hohmann 2018, n=44), not radicular pain.
Chronic Low Back Pain (nonspecific)
Tier BOne small, unblinded randomized trial (Hohmann 2018, n=44): back pain was lower 4 weeks after leech therapy than after exercise therapy; follow-up 8 weeks.
Migraine
Tier CInvestigational use; the only clinical studies found in journal searches are a 7-patient case series and a 26-patient non-randomized pilot (older reports are described in “What the books describe”), and the proposed mechanism is hypothetical.
Tension-Type Headache
Tier CInvestigational use for chronic tension-type headache; no study for this headache type was identified, and the proposed mechanism (muscle tension, venous congestion) is untested.
Essential Hypertension (Adjunctive)
Tier CInvestigational adjunctive use with only non-randomized clinical reports identified; proposed mechanisms are blood-volume removal and hirudin effects on vessels; not a substitute for pharmacotherapy.
Varicose Veins (Symptomatic Tributaries)
Tier CInvestigational use for symptomatic relief of varicose tributary discomfort and inflammation; does not eliminate underlying venous reflux.
Hemorrhoids (Grade II-III, Symptomatic)
Tier CInvestigational use for symptomatic relief of grade II-III internal/external hemorrhoidal disease; does not address anatomic prolapse.
Glaucoma (Adjunctive)
Tier CInvestigational adjunctive use in primary open-angle glaucoma; weak case-series evidence. Not a substitute for IOP-lowering eye drops or surgery.
Dry Eye Syndrome
Tier CInvestigational use for dry eye disease; no clinical study of leech therapy was identified, and the proposed meibomian-gland mechanism is hypothetical.
Lactational Mastitis (Non-Suppurative)
Tier CInvestigational adjunctive use proposed for non-suppurative lactational mastitis; no clinical study of leech therapy was identified.
Fibromyalgia
Tier CInvestigational use only: no controlled clinical study of leech therapy for fibromyalgia was identified, and it is not a primary treatment.
Sciatica (Non-Discogenic / Piriformis)
Tier CInvestigational use for non-discogenic sciatica including piriformis syndrome; no controlled trial, only an old unquantified Russian case series.
Raynaud's Syndrome (Primary)
Tier CInvestigational use for primary Raynaud's phenomenon; the only clinical report is three patients in a 2025 Azerbaijani case series, with no controlled trial.
Livedo Reticularis
Tier CInvestigational use for primary livedo reticularis; no clinical study was identified. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Tier CInvestigational use for chronic lipodermatosclerosis; no study in this condition was identified, only small series in venous ulcer and varicose disease.
Insulin Injection Lipohypertrophy
Tier CInvestigational use for insulin injection-related lipohypertrophy nodules; no clinical study of leech therapy for them was identified.
Androgenic Alopecia
Tier CInvestigational use for androgenic alopecia; the only clinical report is a single-patient Ayurvedic case study, with no controlled trial.
Rosacea (Erythematotelangiectatic)
Tier CInvestigational use for erythematotelangiectatic rosacea; no clinical study of leech therapy was identified.
Plaque Psoriasis (Localized)
Tier CInvestigational adjunct, not a primary treatment; a few small, mostly uncontrolled studies report lower PASI scores.
Atopic Eczema (Localized Refractory)
Tier CInvestigational use for localized refractory eczema; evidence is limited to a few small studies without placebo or standard-care controls.
Keloid and Hypertrophic Scarring
Tier CInvestigational use for keloid and hypertrophic scars; evidence is limited to one small uncontrolled series and two conflicting single-patient reports.
Chronic Recurrent Cellulitis
Tier CInvestigational use for chronic recurrent (non-acute) cellulitis with underlying lymphedema or venous insufficiency.
Primary or Secondary Lymphedema
Tier CInvestigational adjunctive use; no clinical study of leech therapy for lymphedema was identified.
Acute Gout Flare
Tier CInvestigational use for acute monoarticular gout when NSAIDs and colchicine are contraindicated; evidence limited to a few small Ayurvedic pilot studies.
Mid-Substance Achilles Tendinopathy
Tier CInvestigational use for chronic mid-substance Achilles tendinopathy; evidence limited to isolated single-patient reports.
Rotator Cuff Tendinopathy
Tier CInvestigational use for non-surgical rotator cuff tendinopathy and chronic shoulder impingement; evidence limited to isolated case reports.
Trigger Finger (Stenosing Tenosynovitis)
Tier CInvestigational use for stenosing tenosynovitis of the digital flexor pulleys; evidence limited to a single Ayurvedic case report.
Dupuytren's Contracture (Early Stage)
Tier CInvestigational use in Dupuytren's disease; evidence limited to one uncontrolled Russian-language report in patients with contracture.
Plantar Fibromatosis (Ledderhose Disease)
Tier CInvestigational use for plantar fascia nodules in early Ledderhose disease; no clinical study of leech therapy for this condition was identified.
Peyronie's Disease (Stable Phase)
Tier CInvestigational use for stable-phase Peyronie's disease; evidence limited to one uncontrolled Russian series of 29 patients. Standard treatments (verapamil, collagenase, surgery) remain first-line.
Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)
Tier CInvestigational for category III CP/CPPS: evidence is limited to a 3-patient case report, an uncontrolled Russian series and a comparison in urogenital infection; multimodal therapy remains standard.
Endometriosis-Related Pelvic Pain
Tier CInvestigational adjunctive use for chronic endometriosis-related pelvic pain; very limited evidence. Not a substitute for hormonal or surgical management.
Primary Dysmenorrhea
Tier CInvestigational for primary dysmenorrhea; one small randomized trial of leeches plus cupping versus an oral contraceptive pill reported lower pain scores.
Chronic Pelvic Pain Syndrome (Non-Specific)
Tier CInvestigational for non-specific chronic pelvic pain; the only clinical report located is an uncontrolled 60-woman series in which leeches were one part of multimodal care.
Subjective Tinnitus
Tier CInvestigational for tinnitus; small non-randomized studies, mostly Russian, report less ear noise, and no study using the Tinnitus Handicap Inventory was identified.
Ménière's Disease (Adjunctive)
Tier CInvestigational adjunct for Ménière's disease with no clinical study identified; standard management (diet, betahistine, intratympanic therapy) remains primary.
Deep Vein Thrombosis (Post-Acute Phase Symptoms)
Tier CInvestigational use for residual symptoms in the post-acute phase of DVT (>6 weeks); contraindicated in acute DVT.
Showing first 50 of 174. Refine filters to narrow results.
Compounds
119Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Calin
Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.
Saratin
Anti-platelet adhesion protein blocking collagen-mediated platelet activation.
Destabilase
Lysozyme with isopeptidase activity that dissolves stabilized fibrin clots — including aged thrombi resistant to tPA.
Antistasin
Factor Xa inhibitor from the Mexican leech (1987) — used in early animal studies of factor Xa as a target; the DOAC drugs are synthetic and not derived from it.
Decorsin
RGD-containing peptide that inhibits the platelet GP IIb/IIIa receptor; the drug eptifibatide was modelled on snake-venom barbourin, not on decorsin.
Ornatin
RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.
Hementerin
Direct fibrinogenolytic enzyme — degrades fibrinogen independently of plasmin.
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.
Hirudin-PA
Hirudin variant from Hirudinaria manillensis with distinct kinetics.
Hirullin P18
Synthetic hirudin variant with improved oral pharmacokinetics — preclinical anticoagulant.
LCI (Leech Carboxypeptidase Inhibitor)
Inhibitor of TAFI (thrombin-activatable fibrinolysis inhibitor) — synergizes with hirudin's anticoagulant action.
Bivalirudin
Synthetic 20-amino-acid hirudin analog — FDA-approved direct thrombin inhibitor for PCI anticoagulation ($636M peak revenue).
Lepirudin
First-generation recombinant hirudin — FDA-approved 1998 for heparin-induced thrombocytopenia (HIT). Withdrawn 2012 by Bayer for commercial reasons.
Desirudin
Recombinant hirudin variant — FDA-approved 2003 for prophylaxis of DVT after hip replacement surgery.
Dabigatran
Oral direct thrombin inhibitor — FDA approved 2010 for stroke prevention in atrial fibrillation. Synthetic; designed from the inhibitor NAPAP, not derived from hirudin.
Argatroban
Synthetic small-molecule direct thrombin inhibitor — FDA approved 2000 for HIT, later also for PCI in patients with or at risk of HIT. Derived from arginine, not from hirudin.
Rivaroxaban
Oral Factor Xa inhibitor — FDA approved 2011. Synthetic (Bayer, oxazolidinone series); shares its target with the leech protein antistasin but is not derived from it.
Apixaban
Oral Factor Xa inhibitor — FDA approved 2012. Synthetic; shares its target with the leech protein antistasin but is not derived from it.
Edoxaban
Oral Factor Xa inhibitor — FDA approved 2015. Synthetic; shares its target with the leech protein antistasin but is not derived from it.
Eptifibatide
Cyclic heptapeptide GP IIb/IIIa receptor antagonist — FDA approved 1998. Designed from snake-venom barbourin; not derived from the leech.
Hementin
Direct fibrinogenolytic enzyme cleaving fibrinogen alpha-chain at unique sites — independent of plasmin.
Antithrombin III binding protein
Leech-derived inhibitor that potentiates host antithrombin III activity — synergistic anticoagulation.
Therostasin
Factor Xa inhibitor from Theromyzon tessulatum — Kunitz-domain analog with novel selectivity profile.
Haemadin
Picomolar-affinity thrombin inhibitor from Indian buffalo leech — distinct mechanism from hirudin.
Tridegin
Factor XIIIa inhibitor — blocks fibrin cross-linking; novel mechanism distinct from hirudin.
Ixodegrin (leech homolog)
Platelet GP IIb/IIIa antagonist family member — RGD-motif containing.
Destabilase Isopeptidase Activity
Isopeptidase domain of destabilase that cleaves cross-linked fibrin — distinct from lysozyme domain.
Leech Apyrase
ADP-degrading enzyme — prevents platelet aggregation by hydrolyzing ADP at bite site.
Leech Tissue Factor Pathway Inhibitor
Inhibitor of tissue factor / Factor VIIa complex — blocks extrinsic coagulation pathway.
Leech Thrombomodulin-binding factor
Modulates the thrombin-thrombomodulin axis — implications for protein C pathway.
Leech Ecotin-like Factor
Trypsin and Factor Xa inhibitor with broad-spectrum serine protease activity.
Bufrudin
Direct thrombin inhibitor from the Asian buffalo leech — hirudin homolog described in Hirudinaria manillensis secretome.
Haemadipsin
Anticoagulant peptide described in the terrestrial Asian leech Haemadipsa zeylanica.
Whitmanin
Direct thrombin inhibitor homolog cataloged in the Chinese medicinal leech Whitmania pigra secretome.
Piscicolin
Small direct thrombin inhibitor described in the fish leech Piscicola geometra secretome.
Macrobdellin
Anticoagulant peptide described in the North American medicinal leech Macrobdella decora.
Saratin-2
Isoform of saratin — collagen-binding anti-platelet protein from Hirudo medicinalis.
Hementin-Like Protein (HLP-1)
Fibrinogenolytic / anti-platelet protein homologous to hementin — disrupts platelet aggregation.
LAPP-2 (Leech Anti-Platelet Protein, Isoform 2)
Isoform of LAPP — collagen-binding inhibitor of platelet adhesion.
Leech Adhesion-Inhibitor Protein
Salivary protein blocking platelet adhesion to extracellular matrix components.
Destabilase-2
Second isoform of destabilase — lysozyme / isopeptidase activity targeting cross-linked fibrin.
Hirudinase
Alternate fibrin-cleaving enzyme reported in Hirudo medicinalis salivary secretions.
Collagenolytic Fibrinolysin
Dual-function protease degrading both fibrin clot scaffolds and collagen extracellular matrix.
Theromin
Non-hirudin thrombin inhibitor from the rhynchobdellid leech Theromyzon tessulatum — highest-affinity natural inhibitor identified in a non-Hirudo species.
Saratin-3
Collagen-binding antiplatelet variant from the Hirudo medicinalis sialotranscriptome — paralog of saratin and saratin-2.
Hirudonin
Small thrombin-inhibitor peptide identified in the Hirudo medicinalis salivary transcriptome — truncated hirudin-family analog.
Gelin
Antiplatelet peptide identified in leech salivary transcriptome — inhibits platelet aggregation in vitro.
Gelin-2
Paralog of gelin identified in the Hirudo medicinalis sialotranscriptome — putative antiplatelet variant.
Showing first 50 of 119. Refine filters to narrow results.